Physician profile
Michael Ray Harris
NPI 1366493827
$12,610.64
in general payments reported to CMS, 2019-2025
35 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $1,170 · 2021: $1,411 · 2022: $1,816 · 2023: $2,397 · 2024: $2,687 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,124 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,124.00 |
| Education | $113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,735.49 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,301.26 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,006.57 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $847.41 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $825.73 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Sunovion Pharmaceuticals INC. | $802.89 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $773.86 | 2019-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $715.88 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $615.51 | 2019-2025 | Spravato, Xarelto, Invega Sustenna |
| Corium, LLC | $517.74 | 2023-2025 | Azstarys |
| Neuronetics, INC. | $507.05 | 2019-2025 | Neurostar Tms Therapy System |
| Noven Therapeutics, LLC | $488.29 | 2023-2025 | Xelstrym |
| Bausch Health US, LLC | $383.72 | 2020-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $344.31 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $287.26 | 2019-2024 | Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $246.75 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $226.31 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $156.26 | 2020 | |
| Neos Therapeutics, LP | $151.42 | 2020-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $110.11 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $95.47 | 2023-2024 | Quviviq |
| Shire North American Group INC | $71.89 | 2019 | |
| Adlon Therapeutics L.P. | $65.68 | 2020-2021 | |
| Almatica Pharma LLC | $46.49 | 2022-2024 | Loreev Xr |
| Eisai INC. | $40.51 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $35.92 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $35.55 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $34.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.89 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $25.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.08 | 2025 | Cobenfy |
| Abiomed | $15.68 | 2025 | |
| Indivior INC. | $15.48 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $15.04 | 2019 | |
| Tempus Ai, INC | $14.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.